The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

DNA FINANCIAL STATEMENTS

Ginkgo Bioworks Holdings — balance sheet, income statement and cash flow trends

DNAGinkgo Bioworks Holdings

🇺🇸 USA · NYSE · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-2 B020202023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue72.2 M $Gross Profit62.8 M $ · 87%Operating Income-290.7 M $ · -402%Pre-tax Income-295.5 M $ · -409%Net Income to Owners-290.8 M $ · -403%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue72.2 M $-68.7%
Gross Profit62.8 M $-66.0%
Operating Income-290.7 M $—
EBITDA-224.2 M $—
Net Income to Owners-290.8 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
01 B2 B20202023202420252026

Capital Structure

Q2 2026
Total Assets990 M
  • Equity420.3 M $42%
  • Current Liabilities72.7 M $7%
  • Long-term Liabilities497 M $50%

Key Figures

YoY change
Total Assets990 M $-19.6%
Total Liabilities569.8 M $-7.8%
Total Equity420.3 M $-31.4%
Cash & ST Investments302.2 M $-36.2%
Total Debt404.1 M $-5.8%
Net Debt319.6 M $+41.9%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-400 M-200 M020202023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-150 M-100 M-50 M0-167.9 M $Operating56.5 M $Investing18.1 M $Financing-93.3 M $Net Change

Key Figures

YoY change
Operating Cash Flow-167.9 M $—
Capital Expenditures27.5 M $-24.5%
Free Cash Flow-187.8 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on DNA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 3, 26. This content is for informational purposes only and is not investment advice.